GastroenterologyGilead
Gilead Sciences Reports Phase 3 Results for Sofosbuvir-Based Regimens in Hepatitis C
BMI
Biotechnology Media Insights
Editorial Team · July 2, 2023
Gilead Sciences announces Phase 3 trial results showing sofosbuvir-based regimens achieve high rates of sustained virologic response in hepatitis C.
Gilead Sciences today announced Phase 3 trial results for sofosbuvir-based regimens in patients with chronic hepatitis C. The trials demonstrated sustained virologic response rates of over 90% across different genotypes and patient populations, representing a major advance in hepatitis C treatment.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.